Dormant Breast Cancer Cells Slashed 80–87% by Repurposed Drugs in Phase 2 Trial
A randomized trial shows hydroxychloroquine and everolimus can dramatically reduce dormant tumor cells in breast cancer survivors, potentially preventing relapse.
Summary
Breast cancer can return years after treatment because dormant tumor cells hide in bone marrow. Researchers at Penn tested two repurposed drugs — hydroxychloroquine (an antimalarial) and everolimus (an mTOR inhibitor) — in 51 breast cancer survivors who still had detectable dormant tumor cells. After treatment, these cells were reduced by 78–87% depending on the regimen. At three-year follow-up, recurrence-free survival was 91–100% across groups, with better outcomes in patients who cleared their dormant cells entirely. The combination therapy showed the strongest effect. The trial was deemed feasible and safe, with only one patient stopping early due to side effects. These results lay the groundwork for a larger confirmatory trial aimed at preventing breast cancer relapse by eliminating its cellular reservoir.
Detailed Summary
Breast cancer recurrence remains a devastating reality for many survivors, often striking years or even decades after the original diagnosis. The culprit: dormant disseminated tumor cells (DTCs) that linger in bone marrow, evading standard therapies and silently waiting to reactivate. Despite being independently linked to recurrence and death, no approved strategy currently targets these cells.
Researchers at the University of Pennsylvania designed the CLEVER trial (NCT03032406) to test whether two repurposed drugs could eliminate these dormant cells. Hydroxychloroquine (HCQ), which blocks autophagy — a survival mechanism tumor cells exploit during dormancy — and everolimus (EVE), which inhibits mTOR signaling, were tested alone and in combination. The biological rationale was first validated in mouse models, where mTOR inhibition alone or combined with autophagy inhibition significantly depleted residual tumor cells and improved recurrence-free survival.
In the clinical trial, 51 DTC-positive breast cancer survivors were randomized to HCQ, EVE, or HCQ+EVE for three cycles. Posterior probabilities of 98–99.9% confirmed that all three regimens reduced or cleared DTCs compared to observation, with reductions of 80%, 78%, and 87% respectively. Three-year recurrence-free survival reached 91.7%, 92.9%, and 100% for the three arms. Critically, patients who cleared their DTCs had a substantially lower hazard of recurrence (HR = 0.21) than those who did not.
The treatment was well-tolerated across the board, with only one grade 3 toxicity-related discontinuation, a reassuring safety profile for long-term use in cancer survivors.
Caveats include the small sample size, lack of a placebo control arm, and the fact that this was a feasibility/safety-focused phase 2 study — not powered to detect differences in clinical recurrence. The promising DTC clearance data provide proof-of-concept justifying a definitive phase 3 randomized controlled trial.
Key Findings
- HCQ, EVE, and their combination reduced dormant tumor cells by 80%, 78%, and 87% respectively in breast cancer survivors.
- Three-year recurrence-free survival reached 100% in the combination arm vs. ~92% in single-drug arms.
- Patients who cleared dormant tumor cells had an 79% lower hazard of recurrence than those who did not (HR = 0.21).
- Treatment was safe and feasible: only 1 of 51 patients discontinued due to grade 3 toxicity.
- Mouse model data confirm mTOR + autophagy inhibition durably depletes minimal residual disease.
Methodology
This was a randomized phase 2 trial (CLEVER, NCT03032406) enrolling 51 DTC-positive breast cancer survivors within 5 years of diagnosis, randomized to HCQ, EVE, or HCQ+EVE for three cycles. Primary endpoints were feasibility and safety; secondary endpoints included DTC reduction/clearance confirmed via bone marrow aspirate and recurrence-free survival at median 42-month follow-up. Bayesian posterior probability methods were used to estimate DTC reduction versus modeled observation.
Study Limitations
This summary is based on the abstract only, as the full text is not open access. The trial was a small phase 2 study (n=51) primarily designed for feasibility and safety, not powered to demonstrate a statistically significant reduction in clinical recurrence. Absence of a placebo control arm limits causal interpretation of recurrence-free survival outcomes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.